+91-8668442535

Anticoagulant Reversal Drugs Market By Drug Class (Prothrombin Complex Concentrates (PCC), Vitamin K, Protamine, Tranexmic Acid, Desmopressin, Idarucizumab, Andexxa) - Growth, Future Prospects And Competitive Landscape, 2018 – 2026

Industry Outlook

The global anticoagulant reversal drugs market is expected to grow at a compound annual growth rate (CAGR) of 15.3% during the forecast period from 2018 to 2026. Reversing the effects of anticoagulants, including novel oral anticoagulants (NOACs), vitamin K antagonists, and others, is a major concern in clinical practice, especially during life-threatening bleeding episodes and emergency surgery. Approvals of NOACs in the last decade have increased the usage of these factor Xa inhibitors in preventing and treating various medical conditions such as stroke, pulmonary embolism, atrial fibrillation, and deep vein thrombosis (DVT).

However, this growth in anticoagulants' usage has led to a rise in the incidence of hospital admissions and deaths due to increased bleeding due to anticoagulation. According to the Centers for Disease Control and Prevention (CDC), in the year 2016, approximately 117,000 people were hospitalized in the U.S. alone, and close to 2,000 deaths per month were attributable to anticoagulation or factor Xa inhibitor-related bleeding. These factors have led to furious research and the development of anticoagulant reversal agents. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted special status and accelerated approvals for the development and swift market entry of certain anticoagulant antidotes.

Market Synopsis

Recent Approval of the First Reversal Agent for Apixaban and Rivaroxaban Anticoagulants Will Drive the Market

In May 2018, the U.S. FDA approved Andexxa, the first factor Xa inhibitor reversal agent by Portola Pharmaceutical, Inc. The drug can act as an antidote for patients being treated with rivaroxaban (Xarelto) and apixaban (Eliquis) during uncontrolled bleeding and life-threatening situations by reversing anticoagulation effects. Andexxa received both orphan drug status and breakthrough drug designation by the U.S. FDA and has shown prominent clinical efficiency during clinical trials. Increased use of factor Xa inhibitors will drive the market for Andexxa, helping it grow at the fastest rate during the forecast period. Idarucizumab and Prothrombin Complex Concentrates also hold a significant share in the anticoagulant reversal drug market owing to the increased use of these agents during critical situations. Idarucizumab, which was approved in 2015, was the only drug that could reverse dabigatran etexilate mesylate's anticoagulant effects.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments was calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The anticoagulant reversal drugs market report furnishes quantitative analysis along with its latest market trends. The market is segmented based on drug class and geography.

The market is studied in order to understand the current dynamics and future trends in the global anticoagulant reversal drug market. The study includes market size and forecasts for all considered segments presented in the report for the period from 2016 to 2026, along with respective compound annual growth rates (CAGRs) for the forecast period from 2018 to 2026, considering 2017 as the base year.

The key players currently engaged in the anticoagulant reversal drugs market include Boehringer Ingelheim GmbH, Fresenius Kabi AG, Bausch Health Companies, Inc., Pfizer, Inc., CSL Behring Limited, Octapharma AG, Portola Pharmaceuticals, Inc., Perosphere Pharmaceuticals, Inc., and Ferring Pharmaceuticals.

Key questions are answered in this report.

  • How will the global market for anticoagulant reversal drugs perform during the forecast period from 2018 to 2026?
  • What are the most recent trends in the anticoagulant reversal drug market, as well as the most promising opportunities for key players?
  • Who are the leading players in the global anticoagulant reversal drug market?
  • Which is the leading and fastest-growing region in the global anticoagulant reversal drug market?
  • What are the drivers and restraints governing the global anticoagulant reversal drug market?
  • What is the pipeline of anticoagulant reversal drugs on the market?

Frequently Asked Questions:

The market for Anticoagulant Reversal Drugs Market is expected to reach US$ XX Bn By 2026.

The Anticoagulant Reversal Drugs Market is expected to see significant CAGR growth over the coming years, at 15.3%.

The report is forecasted from 2018-2026.

The base year of this report is 2017.

Boehringer Ingelheim GmbH, Fresenius Kabi AG, Bausch Health Companies, Inc., Pfizer, Inc., CSL Behring Limited, Octapharma AG, Portola Pharmaceuticals, Inc., Perosphere Pharmaceuticals, Inc are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Mar 2019
Category:  Pharmaceuticals
Report ID:   59602
Report Format:   PDF
Pages:   120
Rating:    4.4 (66)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support